DD on $ACOG following extension of public offering! Alpha Cognition Inc. ($ACOG $ACOG.v $ACOGF) is a clinical-stage biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases, ex. Alzheimer's and ALS.
$ACOG has patented a new chemical entity that has demonstrated improved tolerability in human clinical trials.
Their drug is being developed as a new inhibitor for the treatment of dementia and is expected to hit the market in 2023.
It commenced an overnight marketed public offering on September 22, 2021, with the intent to use the net proceeds for:
- The clinical development and marketing of its ALPHA formulations
- Working capital and general corporate purposes.
$ACOG recently extended the anticipated closing date of the offering to October 1, 2021.
I'm looking forward to seeing how this is going to affect $ACOG as we currently don't know much about the specifics of the offering as it is being done through a syndicate of agents.
The developments $ACOG has made in treating Alzheimer's have the potential to be lifechanging for so many people and their families, its a shock that they're still so undervalued.
https://www.alphacognition.com/investors/news/alpha-cognition-updates-anticipated-closing-date-of-public-offering